Biogen Inc. (BIIB) Position Lifted by FDx Advisors Inc.

FDx Advisors Inc. lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 19.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,942 shares of the biotechnology company’s stock after purchasing an additional 804 shares during the period. FDx Advisors Inc.’s holdings in Biogen were worth $1,547,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Guardian Life Insurance Co. of America lifted its position in shares of Biogen by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 6 shares in the last quarter. Carroll Financial Associates Inc. increased its holdings in Biogen by 1.2% during the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after buying an additional 6 shares during the last quarter. RMB Capital Management LLC increased its holdings in Biogen by 1.1% during the first quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock worth $223,000 after buying an additional 9 shares during the last quarter. New Amsterdam Partners LLC NY increased its holdings in Biogen by 0.8% during the second quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock worth $399,000 after buying an additional 11 shares during the last quarter. Finally, Alta Capital Management LLC increased its holdings in Biogen by 0.8% during the second quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock worth $510,000 after buying an additional 15 shares during the last quarter. 88.35% of the stock is currently owned by institutional investors.

A number of analysts recently issued reports on the stock. Vetr downgraded shares of Biogen from a “buy” rating to a “hold” rating and set a $298.30 price objective for the company. in a report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) upgraded shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective for the company in a report on Wednesday, August 16th. Mizuho set a $400.00 price objective on shares of Biogen and gave the stock a “buy” rating in a report on Monday. BMO Capital Markets restated a “hold” rating and set a $318.00 price objective on shares of Biogen in a report on Tuesday, July 18th. Finally, Leerink Swann restated a “market perform” rating and set a $338.00 price objective (up previously from $304.00) on shares of Biogen in a report on Wednesday, July 26th. Twelve investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $341.89.

Shares of Biogen Inc. (NASDAQ BIIB) opened at $315.71 on Tuesday. The firm has a market cap of $66,770.00, a P/E ratio of 14.38, a PEG ratio of 1.94 and a beta of 0.72. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46. Biogen Inc. has a 1-year low of $244.28 and a 1-year high of $348.84.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $5.19 EPS. research analysts predict that Biogen Inc. will post 22.03 earnings per share for the current year.

WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/11/14/biogen-inc-biib-position-lifted-by-fdx-advisors-inc.html.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply